Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Apollomics (APLM) and LaunXP International, an affiliate of LaunXP Biomedical, announced that the parties have entered into an agreement for ...

Patients treated with cabozantinib survived significantly longer with no worsening of their disease compared with patients who received placebo ...

Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

A Penn Medicine neurologist was awarded the 2025 John Dystel Prize for his research on immune cells and how they interact to ...

A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

Emma Butler, 32, from Dublin, is encouraging anyone with symptoms - especially women - to not ignore them and go to their GP ...